12 Difficult-to-Pronounce Drug Names, Part 3
With thousands of FDA-approved medications on the market, it can be difficult for pharmacists to stay up-to-date on drug name pronunciations.
Uncertainty Remains in the Match or Mismatch for the 2019-2020 Flu Vaccine
The CDC announced changes to the 2019-20 influenza vaccine with anticipation that it would be better match to the virus than it has been in the past.
Officials from the FDA have expanded the label of insulin aspart injection pumps, 100 u/mL (Fiasp, Novo Nordisk) to include use in insulin infusion pumps.
One in 8 pharmacies closed from 2009 to 2015, despite an overall increase in the number of pharmacies during this time.
This video is sponsored by VaxServe, a Sanofi Pasteur company.
Pegilodecakin in combination with pembrolizumab and nivolumab achieved measurable responses in patients with non-small cell lung cancer and kidney cancer.
The South Carolina business serves its community with compounding, medication adherence packaging, and free delivery and shipping.
The new, standardized, ready-to-use formulation of phenylephrine HCl can help reduce medication errors and improve patient safety.
Top news of the day from across the health care landscape.
At the ESMO Congress 2019, Sara Tolaney, MD, MPH, of Dana-Farber Cancer Institute, spoke about how a collaborative program between pharmacists and oncology providers at her institution helps prevent medication errors.
Trial finds that the addition of anti-HIV immune globulin to standard of care patients with influenza B had a significant virological benefit.
During the 2019 National Association of Specialty Pharmacy Annual Meeting and Expo, Ron Lanton III, Esq, reviewed the FDA Biosimilars Action Plan, its implications for the biosimilar marketplace, recent legislation set to influence the biosimilar pathway and drug accessibility, and the future of the biosimilar market.
First Triple Combo Therapy Approved for Cystic Fibrosis in Adults, Adolescents with F508del Mutation
Elexacaftor/ivacaftor/tezacaftor (Trikafta, Vertex Pharmaceuticals) is indicated for patients aged 12 years and older with cystic fibrosis who have at least 1 F508del mutation.
A panel of experts reviews the benefits of subcutaneous dosing from the patient perspective.
+ Load More